 Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Clinical research reveals the contribution of tepotinib to patients with advanced liver cancer

Br J Cancer: Clinical research reveals the contribution of tepotinib to patients with advanced liver cancer

 Last Update: 2021-04-16
 Source: Internet
 Author: User

Tags

lorazepam 10 mg

breast cancer metastasis lung

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Liver cancer is the third leading cause of cancer-related deaths worldwide, with more than 780,000 people dying from the disease every year.

Previous studies have shown that HCC testing is still late, and only about 30-40% of American/European patients can be treated at the time of diagnosis.

This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.

Percentage of patients with 12-week progression-free survival

In Phase 1b of the trial, patients received 300 or 500 mg of Tepotinib daily.

The primary endpoints of the trial are dose-limiting toxicity (DLT; stage 1b) and 12-week progression-free survival (PFS; stage 2).

Kaplan-Meier curves of PFS, TTP and OS of patients in the phase 2 study

All in all, the clinical trial results revealed that Tepotinib is well tolerated and has shown promising efficacy in RP2D (500mg) .

Tepotinib is well tolerated and has shown promising effects in RP2D (500mg).

org/10.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

N-Desmethyl Imatinib 99%

CAS No.: 404844-02-6

Pharma Grade

$1/MT FOB

Topotecan HCl CAS 119413-54-6 for Scientific Research Chemical Reagents Use only topetecan hydrochloride

CAS No.: 119413-54-6

Pharmacy Grade

$4-5/G FOB

Regorafenib 98% white powder 755037-03-7 Regorafenib (BAY 73-4506)

CAS No.: 755037-03-7

Pharmacy Grade

$4-5/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.